Lara Laini
Overview
Explore the profile of Lara Laini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
31
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pedersini R, Schivardi G, Lagana M, Laini L, di Mauro P, Zamparini M, et al.
Breast
. 2024 Sep;
78:103794.
PMID: 39265313
Purpose: The impact of dietary counseling on body composition in early breast cancer patients (EBC) treated with aromatase inhibitors (AIs) is uncertain. The aim of this study was to assess...
2.
Pedersini R, Buffoni M, Petrelli F, Ghidini A, di Mauro P, Amoroso V, et al.
Clin Breast Cancer
. 2024 May;
24(5):411-420.
PMID: 38734491
Trastuzumab emtansine (T-DM1), sacituzumab govitecan (SG), and trastuzumab deruxtecan (T-DXd) are three ADCs approved for the treatment of metastatic breast cancer (MBC). Since gastrointestinal toxicities have been commonly observed with...
3.
Cosentini D, Pedersini R, di Mauro P, Zamparini M, Schivardi G, Rinaudo L, et al.
JAMA Netw Open
. 2024 Jan;
7(1):e2350950.
PMID: 38198137
Importance: Women with early breast cancer (EBC) exposed to aromatase inhibitors (AIs) may experience fragility fractures despite treatment with bone-active drugs. Risk factors for fractures in patients receiving AIs and...
4.
Pedersini R, Lagana M, Bosio S, Zanini B, Cosentini D, di Mauro P, et al.
Breast Cancer Res Treat
. 2023 Sep;
202(3):461-471.
PMID: 37695400
Purpose: We aimed to investigate the role of a lifestyle intervention and clinical and therapeutic factors for preventing weight gain in early breast cancer (BC) patients from one week before...
5.
di Mauro P, Schivardi G, Pedersini R, Laini L, Esposito A, Amoroso V, et al.
Front Oncol
. 2023 Mar;
13:1139372.
PMID: 36890829
Background: Triple-negative breast cancer (TNBC) is an aggressive cancer subtype, owing to its high metastatic potential: Patients who develop brain metastases (BMs) have a poor prognosis due to the lack...
6.
Pedersini R, Cosentini D, Rinaudo L, Zamparini M, Ulivieri F, di Mauro P, et al.
Bone Rep
. 2023 Jan;
18:101654.
PMID: 36700242
Background: Bone mineral density (BMD) lacks sensitivity in individual fracture risk assessment in early breast cancer (EBC) patients treated with aromatase inhibitors (AIs). New dual-energy X-ray absorptiometry (DXA) based risk...
7.
Pedersini R, di Mauro P, Amoroso V, Castronovo V, Zamparini M, Monteverdi S, et al.
Breast
. 2022 Oct;
66:162-168.
PMID: 36288635
Introduction: Whether adjuvant therapy with aromatase inhibitors (AIs) causes sleep disturbances or not in postmenopausal women with early breast cancer (EBC) is still a controversial issue. Methods: Between March 2014...
8.
Alberti A, Smussi D, Zamparini M, Turla A, Laini L, Marchiselli C, et al.
Front Oncol
. 2022 Oct;
12:997009.
PMID: 36226055
Background: Parathyroid carcinoma (PC) is an extremely rare malignant tumor with an incidence of about 6 new cases per 10 million inhabitants per year. While several papers have been published...
9.
Pedersini R, di Mauro P, Zamparini M, Bosio S, Zanini B, Amoroso V, et al.
In Vivo
. 2022 Jun;
36(4):1860-1867.
PMID: 35738619
Background/aim: Chemotherapy-induced taste alterations (TAs) affect approximately 53-84% of breast cancer patients with significant consequences on flavor perception, possibly leading to food aversion and changes in daily dietary habits. The...